EAHP EU Monitor 13 August 2012

The EAHP EU Monitor is a weekly round up of news relevant to hospital pharmacy in Europe.

You can subscribe to receive the EAHP EU Monitor by email here.


EAHP issues call for abstracts for 2013 Congress

The European Association of Hospital Pharmacists (EAHP) has issued a call for abstracts for its 2013 Congress in Paris.

Any hospital pharmacist may submit an abstract to the EAHP’s Scientific Committee who will then consider its inclusion in the Congress poster display. Accepted abstracts will be published in the official Abstract Book that is issued to all Congress attendees, will be available to view via the EAHP website following the Congress, and will be included in the Congress edition of the European Journal of Hospital Pharmacy (EJHP).

More information here.


Deadline approaches for European Workplaces for All Ages Awards

The European Commission is seeking applications for its Workplaces for all Ages awards. Coinciding with the European Year of Active Ageing the awards initiative is intended to highlight and promote actions taken by employers to promote better working conditions for older employees. 

Any hospital pharmacy considering entering should be aware that the deadline for submissions is 1 September 2012.

More information here.


China takes action on counterfeit medicines

It has been reported in the press that authorities in China have recently launched a crackdown on counterfeit medicine activities, arresting more than 1,900 individuals suspected to be involved in the illegal activity.

The Ministry of Public Security said the fake drugs seized during nationwide raids were advertised for the treatment of hypertensiondiabetesskin diseases and cancer.


EJHP: Clinical pharmacy impact in Austria 

A research article on the impact of clinical pharmacy in an Austrian tertiary care hospital has recently published on the website of the European Journal of Hospital Pharmacy.

The 22-week observational study on six different wards of a hospital analysed the significance of clinical pharmacist interventions and found the mean acceptance rate of interventions was 54.7%. Three out of four clinical pharmacists' interventions were rated to be significant. One out of 20 interventions showed a cost-reducing potential, cancer.

More information here.